Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

Blood - 8 Apr 2010

Beer Philip A, Delhommeau François, LeCouédic Jean-Pierre, Dawson Mark A, Chen Edwin, Bareford David, Kusec Rajko, McMullin Mary Frances, Harrison Claire N, Vannucchi Alessandro M, Vainchenker William, Green Anthony R

Abstract excerpt

Acute myeloid leukemia (AML) may follow a JAK2-positive myeloproliferative neoplasm (MPN), although the mechanisms of disease evolution, often involving loss of mutant JAK2, remain obscure. We studied 16 patients with JAK2-mutant (7 of 16) or JAK2 wild-type (9 of 16) AML after a JAK2-mutant MPN....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blast Crisis
Share to Dioxygenases
Share to Hematologic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Leukemia, Myeloid, Acute

Share to Neoplasms, Second Primary

Share to Primary Myelofibrosis

Share to Proto-Oncogene Proteins c-cbl

Source

Identifiers

PMID: 20008300
DOI: 10.1182/blood-2009-08-236596

Genes

JAK2
TET2
CBL
MPL
NRAS
RUNX1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20008300-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.PMID 20008300Read ↗

Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease acceleratorSemantic proximity Read ↗

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.Semantic proximity Read ↗

Parallel Evolution of Leukemic Clones in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response.Semantic proximity Read ↗

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.Semantic proximity Read ↗

JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.Semantic proximity Read ↗

Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.Semantic proximity Read ↗

Development of chronic myeloid leukemia in a patient previously diagnosed with a JAK2-positive myeloproliferative neoplasm.Semantic proximity Read ↗

Initiating-clone analysis in patients with acute myeloid leukemia secondary to essential thrombocythemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.